E-mail:liliantao@xzhmu.edu.cn
李连涛，医学博士、博士后，副教授、副主任医师、硕士生导师。江苏省“六大高峰人才”、江苏省科教强卫“青年医学人才”、江苏省“科教强卫医学团队”核心成员、徐医附院中青年专家。2010年入职徐州医科大学附属医院肿瘤中心从事临床工作，2020年博士毕业于徐州医科大学。作为访问学者2014年至美国夏威夷大学癌症中心，2018年至美国UNC大学放射治疗系学习。现任徐州医科大学放射治疗与防护教研室副主任、江苏省肿瘤生物治疗工程技术中心副主任、放射肿瘤学学位点秘书。
主要从事恶性肿瘤的精准治疗、肿瘤微环境与免疫治疗等相关研究，先后主持中国博士后基金面上项目、江苏省自然科学基金面上项目等课题10余项。以第一或通讯作者发表SCI论文30余篇。曾获教育部自然科学奖二等奖（排名第三）、中华医学奖二等奖(排名第七)、年江苏省科学技术奖三等奖（排名第六）等省市级奖项10余项。
联系方式
邮箱：liliantao@xzhmu.edu.cn
代表性论文（*通讯作者）
1、HanL,*, ChenY,WuR, ChenJ, ChenZ, CaiY,HuangS, Gu Ha, ZhuangX, LvY, LiH, LiLiantao*, WangG*。Tumor-Derived Exosomal Fatty Acids Reprogram Neutrophils to Drive Neutrophil Extracellular Traps Formation and Lung Cancer Progression.Research (Wash D C). 2026 May 11;9:1278.Q1 IF:10.9
2、Yuan S, Chen J, Cheng G, Deng S, Wang J, Wang B,Li L*.The role of postoperative radiation therapy in early-stage tongue carcinoma: A systematic review and meta-analysis.J Stomatol Oral Maxillofac Surg. 2025 Jun;126(3S):102192.Q3 IF: 4.0
3、Wang J, Deng S, Cheng G, Wang Y, Shen Y, Chen J, Xu K, Wang B, Han S,Li L*. Relationships between blood cadmium concentration and risk of nine cancers: evidence from the NHANES 1999-2018 and Mendelian randomization analyses. Discov Oncol. 2024 Dec 22;15(1):823. Q2IF:2.8
4、Shang Y, Wang J, Feng Y, Liu Z, Lu J, Deng S, Li L, Zhang H,Li L*, Wang Z*, Yang Z*. A dual-targeted trinity of antibody-peptide-drug delivery consortium to combat HER2+ tumor. Chem Commun (Camb). 2024 Nov 19;60(93):13742-13745. Q2IF:4.4
5、Li L#, Qu D, Wang B, Yuan S, Zhao Y , Liu N, Huo F, Zhang D, Zhang L..FTO blocks RNA translational activity via the loss of N6-methyladenosine methylation at 5' UTR regulated by RBM5 in cisplatin-resistant NSCLC. J Cell Physiol.2024 May 14. doi: 10.1002/jcp.31296. Online ahead of print. Q2 IF:6.40
6、Wang G#, Zhou X, Guo Z, Huang Nan, Li J, Lv Y, Han L, Zheng W, Xu D, Chai D, Li H,Li L*, Zheng J*.The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. Cancer Biol Ther, 2022, 31;23(1):150-162. Q2 IF :3.6
7、Zhao Y#, Zhao H, Zhang D, Q Q, Ge Y,Li L*, Guo L*. YTHDF3 Facilitates eIF2AK2 and eIF3A Recruitment on mRNAs to Regulate Translational Processes in Oxaliplatin-Resistant Colorectal Cancer. ACS Chem Biol, 2022, 15;17(7):1778-1788. Q2 IF: 4.0
8、Liu G#, Lu Y#,Li L#, Jiang T, Chu S, Hou P, Bai J*, Chen M*.The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma. Invest New Drugs, 2020,38(6):1730-1742. Q2 IF :3.85
9、Li L#, Li N#, Liu N, Huo F, Zheng J*.MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma. Onco Targets Ther. 2020, 7;13:10001-10012. Q2 IF :4.147
10、Yang F#, Medik Y#,Li L#, Tian X, Fu D, Brouwer KLR, Wagner K, Sun B, Sendi H, Mi Y*, Wang AZ*. Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo. Small, 2020, 16(7): e1906360. Q1 IF :13.281
领导信箱